Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Septerna Inc (SEPN)
USD34.00
-0.54 (-1.56%)
US NASDAQ Healthcare Biotechnology
Address
250 East Grand Avenue 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Jeffrey T. Finer
Website
septerna.com
IPO
2024-10-25
CIK 1984086 ISIN US81734D1046
Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD34.00
-0.54 (-1.56%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
378.0K
Beta
2.38
Float Shares
18.88M
Free Float %
41.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.39% | +0.28% | +7.58% | -3.57% | +29.17% | -10.90% | +255.87% | +16.07% | +16.07% | +16.07% | +16.07% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
34.00
Low
28.00
-17.6%
Consensus
39.00
+14.7%
Median
35.00
+2.9%
High
60.00
+76.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
60.00
+76.5%
|
| Last Year | 6 |
35.50
+4.4%
|
| All Time | 8 |
29.75
-12.5%
|
Quality scores
Altman Z-Score
3.23
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+4,174.5% ★ Q1'26: +12,011.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+84.9% ★ Q1'26: +61.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+180.7% Q1'26: -99.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-175.8% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-558.7% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+347.5% Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.30× Q1'26: -0.43× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 6 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.08M
est: 719.0K (+49.5%)
|
45.95M
est: 38.37M (+19.8%)
|
65.68M
45.55M – 93.51M
+71.2% YoY
|
59.83M
36.62M – 77.53M
-8.9% YoY
|
63.76M
41.87M – 87.09M
+6.6% YoY
|
50.08M
32.88M – 68.40M
-21.5% YoY
|
86.16M
56.58M – 117.69M
+72.1% YoY
|
| EBITDA |
-79.42M
est: -359.5K (-21,992.4%)
|
-79.19M
est: -19.18M (-312.8%)
|
-32.84M
-46.76M – -22.77M
-71.2% YoY
|
-29.92M
-38.76M – -18.31M
+8.9% YoY
|
-31.88M
-43.55M – -20.93M
-6.6% YoY
|
-25.04M
-34.20M – -16.44M
+21.5% YoY
|
-43.08M
-58.84M – -28.29M
-72.1% YoY
|
| EBIT |
-80.82M
est: -359.5K (-22,382.1%)
|
-80.80M
est: -19.18M (-321.2%)
|
-32.84M
-46.76M – -22.77M
-71.2% YoY
|
-29.92M
-38.76M – -18.31M
+8.9% YoY
|
-31.88M
-43.55M – -20.93M
-6.6% YoY
|
-25.04M
-34.20M – -16.44M
+21.5% YoY
|
-43.08M
-58.84M – -28.29M
-72.1% YoY
|
| Net Income |
-71.80M
est: -375.82M (+80.9%)
|
-48.88M
est: -48.88M (+0.0%)
|
-89.44M
-161.16M – -29.14M
-83.0% YoY
|
-130.43M
-156.30M – -64.18M
-45.8% YoY
|
-115.16M
-155.33M – -74.99M
+11.7% YoY
|
-153.58M
-226.64M – -85.03M
-33.4% YoY
|
-167.65M
-247.41M – -92.82M
-9.2% YoY
|
| SGA |
16.56M
est: 14.64M (+13.2%)
|
29.16M
est: 781.06M (-96.3%)
|
1.34B
927.14M – 1.90B
+71.2% YoY
|
1.22B
745.39M – 1.58B
-8.9% YoY
|
1.30B
852.29M – 1.77B
+6.6% YoY
|
1.02B
669.36M – 1.39B
-21.5% YoY
|
1.75B
1.15B – 2.40B
+72.1% YoY
|
| EPS |
-7.26
est: -7.76 (+6.4%)
|
-1.10
est: -1.12 (+1.6%)
|
-1.87
-3.64 – -0.66
-66.9% YoY
|
-2.51
-3.53 – -1.45
-34.3% YoY
|
-2.61
-3.51 – -1.69
-4.1% YoY
|
-3.47
-5.12 – -1.92
-33.0% YoY
|
-3.79
-5.59 – -2.10
-9.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
215.27M
OE per share TTM
4.72
Owner's Yield
19.36%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
152.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
23
Total invested
7.20M
Insider transactions (90d)
0
Beneficial owners (>5%)
17
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 7.00M | 15.80% | — | 7.00M | — | 10.00 | HC, IN | United States | 2024-11-04 | ↗ |
| 2 | RA Capital Management, L.P. | 7.00M | 15.80% | — | 7.00M | — | 10.00 | IA, PN | Delaware | 2024-11-04 | ↗ |
| 3 | Rajeev Shah | 7.00M | 15.80% | — | 7.00M | — | 10.00 | HC, IN | United States | 2024-11-04 | ↗ |
| 4 | RA Capital Healthcare Fund, L.P. | 5.52M | 12.40% | — | 5.52M | — | 10.00 | PN | Delaware | 2024-11-04 | ↗ |
| 5 | Samsara BioCapital GP, LLC | 2.77M | 6.20% | — | 2.77M | — | — | OO | Delaware | 2024-11-04 | ↗ |
| 6 | Samsara BioCapital, L.P. | 2.77M | 6.20% | — | 2.77M | — | — | PN | Delaware | 2024-11-04 | ↗ |
| 7 | Srinivas Akkaraju | 2.77M | 6.20% | — | 2.77M | — | — | IN | Delaware | 2024-11-04 | ↗ |
| 8 | BVF Inc. | 2.45M | 5.50% | — | — | — | 2.45M | CO | Delaware | 2024-11-01 | ↗ |
| 9 | BVF Partners L.P. | 2.45M | 5.50% | — | — | — | 2.45M | IA, PN | Delaware | 2024-11-01 | ↗ |
| 10 | Mark N. Lampert | 2.45M | 5.50% | — | — | — | 2.45M | IN | Delaware | 2024-11-01 | ↗ |
| 11 | BVF GP Holdings LLC | 2.30M | 5.20% | — | — | — | 2.30M | OO | Delaware | 2024-11-01 | ↗ |
| 12 | BVF I GP LLC | 1.30M | 2.90% | — | — | — | 1.30M | OO | Delaware | 2024-11-01 | ↗ |
| 13 | Biotechnology Value Fund, L.P. | 1.30M | 2.90% | — | — | — | 1.30M | PN | Delaware | 2024-11-01 | ↗ |
| 14 | BVF II GP LLC | 998.6K | 2.20% | — | — | — | 998.6K | OO | Delaware | 2024-11-01 | ↗ |
| 15 | Biotechnology Value Fund II, L.P. | 998.6K | 2.20% | — | — | — | 998.6K | PN | Delaware | 2024-11-01 | ↗ |
| 16 | BVF Partners OS Ltd. | 133.0K | 1.00% | — | — | — | 133.0K | CO | Delaware | 2024-11-01 | ↗ |
| 17 | Biotechnology Value Trading Fund OS LP | 133.0K | 1.00% | — | — | — | 133.0K | PN | Delaware | 2024-11-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
23
-104 vs prev Q
New positions
2
Closed positions
103
Increased
15
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 194.5K +194.5K (+100.0%) | 5.42B +5.4B (+100.0%) | 0.44% +0.439 pp | 5.36% +5.365 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 7.00M +— (+0.0%) | 195.04M +63.5M (+48.2%) | 15.78% -0.064 pp | 2.00% +0.377 pp | USD22.90 +21.7% | 5 qtrs — |
| 3 | TRV GP V, LLC | 6.22M +— (+0.0%) | 173.29M +56.4M (+48.2%) | 14.02% -0.057 pp | 40.38% +7.304 pp | USD22.90 +21.7% | 5 qtrs — |
| 4 | DRIEHAUS CAPITAL MANAGEMENT LLC | 4.81M -110.4K (-2.2%) | 134.09M +41.5M (+44.9%) | 10.85% -0.294 pp | 0.91% +0.248 pp | USD16.94 +64.6% | 5 qtrs — |
| 5 | TRV GP VI, LLC | 4.21M +— (+0.0%) | 117.42M +38.2M (+48.2%) | 9.50% -0.038 pp | 79.05% +6.789 pp | USD18.60 +49.9% | 5 qtrs — |
| 6 | SAMSARA BIOCAPITAL, LLC | 3.15M +— (+0.0%) | 87.80M +28.6M (+48.2%) | 7.10% -0.029 pp | 9.06% +1.325 pp | USD20.83 +33.8% | 5 qtrs — |
| 7 | GOLDMAN SACHS GROUP INC | 2.72M +1.3M (+86.6%) | 75.70M +48.3M (+176.6%) | 6.12% +2.829 pp | 0.01% +0.006 pp | USD25.15 +10.9% | 5 qtrs — |
| 8 | SIREN, L.L.C. | 2.00M -202.5K (-9.2%) | 55.76M +14.3M (+34.6%) | 4.51% -0.477 pp | 1.66% +0.043 pp | USD22.90 +21.7% | 5 qtrs — |
| 9 | BLACKROCK, INC. | 1.80M +341.5K (+23.4%) | 50.22M +22.8M (+82.9%) | 4.06% +0.757 pp | 0.00% +0.000 pp | USD22.78 +22.4% | 5 qtrs — |
| 10 | BVF INC/IL | 1.72M -2.3M (-57.1%) | 47.98M -27.6M (-36.5%) | 3.88% -5.212 pp | 1.61% -1.447 pp | USD15.33 +81.9% | 5 qtrs — |
| 11 | VANGUARD GROUP INC | 1.51M -10.6K (-0.7%) | 42.05M +13.5M (+47.2%) | 3.40% -0.038 pp | 0.00% +0.000 pp | USD19.10 +46.0% | 5 qtrs — |
| 12 | AVORO CAPITAL ADVISORS LLC | 1.34M +— (+0.0%) | 37.29M +12.1M (+48.2%) | 3.02% -0.012 pp | 0.36% +0.033 pp | USD19.90 +40.1% | 5 qtrs — |
| 13 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.16M -18.9K (-1.6%) | 32.27M +10.1M (+45.8%) | 2.61% -0.053 pp | 2.37% +0.292 pp | USD9.95 +180.2% | 4 qtrs — |
| 14 | FIRST LIGHT ASSET MANAGEMENT, LLC | 620.8K +620.8K (+100.0%) | 17.31M +17.3M (+100.0%) | 1.40% +1.400 pp | 1.32% +1.323 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 15 | VR ADVISER, LLC | 610.8K +— (+0.0%) | 17.03M +5.5M (+48.2%) | 1.38% -0.006 pp | 0.84% +0.195 pp | USD11.52 +142.0% | 3 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 572.7K +27.0K (+5.0%) | 15.97M +5.7M (+55.6%) | 1.29% +0.056 pp | 0.00% +0.000 pp | USD20.17 +38.2% | 5 qtrs — |
| 17 | CASDIN CAPITAL, LLC | 553.3K +— (+0.0%) | 15.43M +5.0M (+48.2%) | 1.25% -0.005 pp | 0.96% +0.090 pp | USD22.90 +21.7% | 5 qtrs — |
| 18 | PRIMECAP MANAGEMENT CO/CA/ | 546.1K +546.1K (+100.0%) | 15.23M +15.2M (+100.0%) | 1.23% +1.232 pp | 0.01% +0.012 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 19 | STATE STREET CORP | 540.0K +121.1K (+28.9%) | 15.06M +7.2M (+91.1%) | 1.22% +0.269 pp | 0.00% +0.000 pp | USD20.79 +34.1% | 5 qtrs — |
| 20 | PERCEPTIVE ADVISORS LLC | 433.2K -108.3K (-20.0%) | 12.08M +1.9M (+18.6%) | 0.98% -0.249 pp | 0.22% -0.079 pp | USD10.57 +163.8% | 5 qtrs — |
| 21 | WOODLINE PARTNERS LP | 385.3K +102.7K (+36.4%) | 10.74M +5.4M (+102.1%) | 0.87% +0.229 pp | 0.04% +0.017 pp | USD18.14 +53.7% | 5 qtrs — |
| 22 | SOLEUS CAPITAL MANAGEMENT, L.P. | 383.4K +365.1K (+1,999.5%) | 10.69M +10.3M (+3,011.8%) | 0.86% +0.823 pp | 0.39% +0.377 pp | USD27.56 +1.2% | 5 qtrs — |
| 23 | CATALIO CAPITAL MANAGEMENT, LP | 294.4K +— (+0.0%) | 8.21M +2.7M (+48.2%) | 0.66% -0.003 pp | 1.45% +0.427 pp | USD22.90 +21.7% | 5 qtrs — |
| 24 | MARSHALL WACE, LLP | 226.9K +226.9K (+100.0%) | 6.33M +6.3M (+100.0%) | 0.51% +0.512 pp | 0.01% +0.006 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 25 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 222.7K +— (+0.0%) | 6.21M +2.0M (+48.2%) | 0.50% -0.002 pp | 0.01% +0.003 pp | USD16.26 +71.5% | 5 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 187.2K +337.0 (+0.2%) | 5.22M +1.7M (+48.5%) | 0.42% -0.001 pp | 0.00% +0.000 pp | USD19.81 +40.7% | 5 qtrs — |
| 27 | INVESCO LTD. | 162.0K -15.1K (-8.5%) | 4.52M +1.2M (+35.6%) | 0.37% -0.036 pp | 0.00% +0.000 pp | USD19.08 +46.1% | 5 qtrs — |
| 28 | NORTHERN TRUST CORP | 154.2K -13.1K (-7.9%) | 4.30M +1.2M (+36.6%) | 0.35% -0.031 pp | 0.00% +0.000 pp | USD21.56 +29.3% | 5 qtrs — |
| 29 | MILLENNIUM MANAGEMENT LLC | 107.5K -276.7K (-72.0%) | 3.00M -4.2M (-58.5%) | 0.24% -0.628 pp | 0.00% -0.002 pp | USD17.05 +63.5% | 4 qtrs — |
| 30 | MORGAN STANLEY | 104.0K +49.5K (+90.9%) | 2.90M +1.9M (+183.0%) | 0.23% +0.111 pp | 0.00% +0.000 pp | USD20.44 +36.4% | 5 qtrs — |
| 31 | TWO SIGMA INVESTMENTS, LP | 92.8K +475.0 (+0.5%) | 2.59M +850.7K (+49.0%) | 0.21% +0.000 pp | 0.00% +0.001 pp | USD8.11 +243.8% | 4 qtrs — |
| 32 | JANE STREET GROUP, LLC | 80.2K -272.2K (-77.2%) | 2.24M -4.4M (-66.3%) | 0.18% -0.617 pp | 0.00% -0.001 pp | USD10.10 +176.0% | 4 qtrs — |
| 33 | FEDERATED HERMES, INC. | 78.9K +78.9K (+100.0%) | 2.20M +2.2M (+100.0%) | 0.18% +0.178 pp | 0.00% +0.004 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 34 | HIGHVISTA STRATEGIES LLC | 78.7K +78.7K (+100.0%) | 2.19M +2.2M (+100.0%) | 0.18% +0.177 pp | 0.56% +0.565 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 35 | CITADEL ADVISORS LLC | 75.9K +75.9K (+100.0%) | 2.12M +2.1M (+100.0%) | 0.17% +0.171 pp | 0.00% +0.000 pp | USD27.88 +0.0% | 5 qtrs — |
| 36 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 69.2K -3.4K (-4.7%) | 1.93M +563.7K (+41.3%) | 0.16% -0.008 pp | 0.00% +0.000 pp | USD14.47 +92.7% | 4 qtrs — |
| 37 | UBS GROUP AG | 68.8K +9.8K (+16.5%) | 1.92M +808.0K (+72.7%) | 0.16% +0.022 pp | 0.00% +0.000 pp | USD15.56 +79.2% | 5 qtrs — |
| 38 | JPMORGAN CHASE & CO | 68.3K +59.6K (+682.3%) | 1.91M +1.7M (+1,059.5%) | 0.15% +0.134 pp | 0.00% +0.000 pp | USD27.04 +3.1% | 5 qtrs — |
| 39 | RANGELEY CAPITAL, LLC | 65.8K -22.2K (-25.2%) | 1.83M +179.2K (+10.8%) | 0.15% -0.051 pp | 1.52% +0.091 pp | USD10.45 +166.8% | 4 qtrs — |
| 40 | JACOBS LEVY EQUITY MANAGEMENT, INC | 61.4K +25.6K (+71.5%) | 1.71M +1.0M (+154.2%) | 0.14% +0.057 pp | 0.01% +0.004 pp | USD22.59 +23.4% | 2 qtrs — |
| 41 | BANK OF NEW YORK MELLON CORP | 55.3K +3.7K (+7.2%) | 1.54M +571.5K (+58.8%) | 0.12% +0.008 pp | 0.00% +0.000 pp | USD20.66 +34.9% | 5 qtrs — |
| 42 | AMERICAN CENTURY COMPANIES INC | 50.7K +25.4K (+100.5%) | 1.41M +937.6K (+197.2%) | 0.11% +0.057 pp | 0.00% +0.001 pp | USD23.36 +19.3% | 2 qtrs — |
| 43 | LONGAEVA PARTNERS L.P. | 49.9K -7.2K (-12.6%) | 1.39M +317.9K (+29.6%) | 0.11% -0.017 pp | 0.12% -0.038 pp | USD18.81 +48.2% | 2 qtrs — |
| 44 | NUMERAI GP LLC | 45.9K +45.9K (+100.0%) | 1.28M +1.3M (+100.0%) | 0.10% +0.103 pp | 0.15% +0.154 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 45 | TREXQUANT INVESTMENT LP | 44.0K +44.0K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.10% +0.099 pp | 0.01% +0.011 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 46 | BARCLAYS PLC | 38.1K +8.0K (+26.7%) | 1.06M +497.3K (+87.8%) | 0.09% +0.018 pp | 0.00% +0.000 pp | USD20.42 +36.5% | 5 qtrs — |
| 47 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 37.9K +37.9K (+100.0%) | 1.06M +1.1M (+100.0%) | 0.09% +0.085 pp | 0.01% +0.008 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 48 | BANK OF AMERICA CORP /DE/ | 37.6K -13.9K (-27.0%) | 1.05M +79.5K (+8.2%) | 0.08% -0.032 pp | 0.00% +0.000 pp | USD12.01 +132.1% | 5 qtrs — |
| 49 | ALYESKA INVESTMENT GROUP, L.P. | 35.0K +— (+0.0%) | 975.8K +317.5K (+48.2%) | 0.08% 0.000 pp | 0.00% +0.001 pp | USD22.90 +21.7% | 5 qtrs — |
| 50 | ALGERT GLOBAL LLC | 34.9K +34.9K (+100.0%) | 974.0K +974.0K (+100.0%) | 0.08% +0.079 pp | 0.02% +0.015 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 51 | ACADIAN ASSET MANAGEMENT LLC | 30.9K +30.9K (+100.0%) | 858.0K +858.0K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.001 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 52 | WELLS FARGO & COMPANY/MN | 26.5K +6.4K (+31.7%) | 739.6K +360.7K (+95.2%) | 0.06% +0.014 pp | 0.00% +0.000 pp | USD21.33 +30.7% | 5 qtrs — |
| 53 | RHUMBLINE ADVISERS | 26.4K -1.2K (-4.3%) | 736.6K +217.3K (+41.9%) | 0.06% -0.003 pp | 0.00% +0.000 pp | USD18.64 +49.6% | 5 qtrs — |
| 54 | NUVEEN, LLC | 25.8K +1.8K (+7.7%) | 719.2K +268.5K (+59.6%) | 0.06% +0.004 pp | 0.00% +0.000 pp | USD9.97 +179.6% | 4 qtrs — |
| 55 | TWO SIGMA ADVISERS, LP | 25.7K +5.0K (+24.2%) | 716.5K +327.1K (+84.0%) | 0.06% +0.011 pp | 0.00% +0.001 pp | USD20.57 +35.5% | 2 qtrs — |
| 56 | PRICE T ROWE ASSOCIATES INC /MD/ | 25.4K -2.0K (-7.2%) | 710.0K +194.0K (+37.6%) | 0.06% -0.005 pp | 0.00% +0.000 pp | USD21.65 +28.8% | 5 qtrs — |
| 57 | LOGOS GLOBAL MANAGEMENT LP | 23.5K -60.0K (-71.8%) | 656.5K -915.0K (-58.2%) | 0.05% -0.136 pp | 0.04% -0.101 pp | USD22.90 +21.7% | 5 qtrs — |
| 58 | XTX TOPCO LTD | 23.3K +23.3K (+100.0%) | 650.0K +650.0K (+100.0%) | 0.05% +0.053 pp | 0.02% +0.017 pp | USD27.88 +0.0% | 4 qtrs — |
| 59 | ALLIANCEBERNSTEIN L.P. | 19.6K -2.5K (-11.3%) | 546.4K +130.7K (+31.5%) | 0.04% -0.006 pp | 0.00% +0.000 pp | USD10.57 +163.8% | 3 qtrs — |
| 60 | TUDOR INVESTMENT CORP ET AL | 18.1K +18.1K (+100.0%) | 503.3K +503.3K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.001 pp | USD27.88 +0.0% | 3 qtrs — |
| 61 | FRANKLIN RESOURCES INC | 16.9K +16.9K (+100.0%) | 469.8K +469.8K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 62 | RUSSELL INVESTMENTS GROUP, LTD. | 15.3K +13.4K (+707.5%) | 426.8K +391.2K (+1,096.9%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD26.76 +4.2% | 2 qtrs — |
| 63 | DEUTSCHE BANK AG\ | 14.9K +744.0 (+5.3%) | 414.8K +148.9K (+56.0%) | 0.03% +0.002 pp | 0.00% +0.000 pp | USD17.75 +57.1% | 5 qtrs — |
| 64 | SQUAREPOINT OPS LLC | 14.8K +14.8K (+100.0%) | 413.9K +413.9K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD27.88 +0.0% | 3 qtrs — |
| 65 | STRS OHIO | 14.6K +14.6K (+100.0%) | 407.0K +407.0K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.002 pp | USD27.88 +0.0% | 5 qtrs — |
| 66 | LOS ANGELES CAPITAL MANAGEMENT LLC | 18.6K +18.6K (+100.0%) | 398.6K +398.6K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.001 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 67 | AMERIPRISE FINANCIAL INC | 14.1K +14.1K (+100.0%) | 392.8K +392.8K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 68 | METLIFE INVESTMENT MANAGEMENT, LLC | 13.7K +— (+0.0%) | 381.5K +124.1K (+48.2%) | 0.03% 0.000 pp | 0.00% +0.001 pp | USD10.57 +163.8% | 5 qtrs — |
| 69 | INTECH INVESTMENT MANAGEMENT LLC | 13.3K +13.3K (+100.0%) | 370.3K +370.3K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.003 pp | USD27.88 +0.0% | 3 qtrs — |
| 70 | ADVISOR GROUP HOLDINGS, INC. | 12.7K -170.0 (-1.3%) | 353.9K +111.9K (+46.3%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD18.67 +49.3% | 3 qtrs — |
| 71 | DYNAMIC TECHNOLOGY LAB PRIVATE LTD | 10.8K +10.8K (+100.0%) | 301.0K +301.0K (+100.0%) | 0.02% +0.024 pp | 0.07% +0.068 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 72 | PHARVISION ADVISERS, LLC | 10.7K -1.2K (-10.0%) | 299.4K +75.0K (+33.4%) | 0.02% -0.003 pp | 0.15% +0.025 pp | USD11.80 +136.3% | 3 qtrs — |
| 73 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 10.6K +10.6K (+100.0%) | 295.4K +295.4K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.001 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 74 | VIRTUS INVESTMENT ADVISERS, INC. | 10.5K +10.5K (+100.0%) | 291.5K +291.5K (+100.0%) | 0.02% +0.024 pp | 0.08% +0.079 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 75 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 10.3K +10.3K (+100.0%) | 287.1K +287.1K (+100.0%) | 0.02% +0.023 pp | 0.02% +0.022 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 76 | BAADER BANK AKTIENGESELLSCHAFT | 10.0K +10.0K (+100.0%) | 278.8K +278.8K (+100.0%) | 0.02% +0.023 pp | 0.02% +0.019 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 77 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 9.9K +143.0 (+1.5%) | 277.0K +92.8K (+50.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD21.56 +29.3% | 5 qtrs — |
| 78 | ATOM INVESTORS LP | 9.8K +9.8K (+100.0%) | 273.0K +273.0K (+100.0%) | 0.02% +0.022 pp | 0.02% +0.022 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 79 | CITIGROUP INC | 9.6K +9.3K (+3,739.8%) | 266.6K +261.9K (+5,590.9%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD27.48 +1.5% | 5 qtrs — |
| 80 | GRAHAM CAPITAL MANAGEMENT, L.P. | 9.0K +9.0K (+100.0%) | 250.1K +250.1K (+100.0%) | 0.02% +0.020 pp | 0.01% +0.006 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 81 | JUMP FINANCIAL, LLC | 8.4K +8.4K (+100.0%) | 234.2K +234.2K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.003 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 82 | BANK OF NOVA SCOTIA | 8.3K +8.3K (+100.0%) | 231.4K +231.4K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 83 | AQR CAPITAL MANAGEMENT LLC | 7.8K +7.8K (+100.0%) | 218.2K +218.2K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 84 | NEW YORK STATE COMMON RETIREMENT FUND | 5.6K +2.7K (+93.1%) | 156.1K +101.6K (+186.2%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD20.72 +34.6% | 5 qtrs — |
| 85 | BNP PARIBAS ARBITRAGE, SNC | 5.4K +1.3K (+31.1%) | 151.9K +73.8K (+94.4%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD20.22 +37.9% | 5 qtrs — |
| 86 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 5.2K +— (+0.0%) | 144.3K +46.9K (+48.2%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD9.87 +182.5% | 4 qtrs — |
| 87 | BALYASNY ASSET MANAGEMENT L.P. | 3.6K +3.6K (+100.0%) | 99.6K +99.6K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 88 | FMR LLC | 3.3K -131.0 (-3.8%) | 92.2K +27.5K (+42.6%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD21.77 +28.1% | 5 qtrs — |
| 89 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 3.2K +3.2K (+100.0%) | 88.4K +88.4K (+100.0%) | 0.01% +0.007 pp | 0.02% +0.022 pp | USD27.88 +0.0% | 3 qtrs — |
| 90 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 2.2K +2.2K (+100.0%) | 60.7K +60.7K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD27.88 +0.0% | 1 qtrs NEW |
| 91 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.2K +1.2K (+124.8%) | 60.1K +42.1K (+233.2%) | 0.00% +0.003 pp | 0.00% +0.001 pp | USD22.21 +25.5% | 5 qtrs — |
| 92 | AMERITAS INVESTMENT PARTNERS, INC. | 1.9K +— (+0.0%) | 54.2K +17.6K (+48.2%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD22.90 +21.7% | 5 qtrs — |
| 93 | LEGAL & GENERAL GROUP PLC | 1.9K +— (+0.0%) | 54.2K +17.6K (+48.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD22.23 +25.4% | 5 qtrs — |
| 94 | COVESTOR LTD | 1.9K -1.7K (-46.4%) | 54.0K -14.0K (-20.6%) | 0.00% -0.004 pp | 0.03% -0.009 pp | USD13.52 +106.2% | 3 qtrs — |
| 95 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 1.3K -55.0 (-4.0%) | 36.7K +10.9K (+42.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.33 +340.4% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 93 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.06% | 5.01M | 0.35% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.62% | 354.1K | 0.65% |
| 3 | First Trust Multi-Manager Small Cap Opportunities ETF MMSC | 0.52% | 277.2K | 0.95% |
| 4 | American Century Small Cap Growth Insights ETF ACSG | 0.23% | 57.3K | 0.49% |
| 5 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.22% | 51.5K | 1.22% |
| 6 | Royce Quant Small-Cap Quality Value ETF SQLV | 0.19% | 55.6K | 0.60% |
| 7 | iShares U.S. Pharmaceuticals ETF IHE | 0.19% | 2.48M | 0.38% |
| 8 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.15% | 246.3K | 0.51% |
| 9 | JPMorgan Diversified Return U.S. Small Cap Equity ETF JPSE | 0.11% | 670.9K | 0.29% |
| 10 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.11% | 515.7K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.25
Bearish
Ratio by volume
0.50
Neutral
Buys
1
Sells
4
Shares acquired
4.0K
Shares disposed
8.0K
Cash buys
—
Cash sales
3.00
Net activity
-4,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Bhatt Elizabeth | Officer | M-Exempt | A | Common Stock | 4,000 | 6.81 | 27.2K | 178,209 | D | ↗ |
| 2026-03-02 | Shaikhly Samira | Officer | M-Exempt | A | Common Stock | 53,714 | 1.55 | 83.3K | 54,507 | D | ↗ |
| 2026-02-18 | Bhatt Elizabeth | Officer | M-Exempt | A | Common Stock | 4,000 | 6.81 | 27.2K | 178,209 | D | ↗ |
| 2026-02-06 | Wilson Mark Andrew | Officer | A-Award | A | Stock Option (Right to Buy) | 165,000 | 25.41 | 4.19M | 165,000 | D | ↗ |
| 2026-02-06 | Shaikhly Samira | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 25.41 | 2.03M | 80,000 | D | ↗ |
| 2026-02-06 | Long Daniel D. | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 25.41 | 2.03M | 80,000 | D | ↗ |
| 2026-02-06 | Labrucherie Gil M | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 25.41 | 3.18M | 125,000 | D | ↗ |
| 2026-02-06 | Klein Uwe | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 25.41 | 2.03M | 80,000 | D | ↗ |
| 2026-02-06 | Kim Jae B. | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 25.41 | 3.18M | 125,000 | D | ↗ |
| 2026-02-06 | Finer Jeffrey | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 25.41 | 10.16M | 400,000 | D | ↗ |
| 2026-02-06 | Bhatt Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 155,000 | 25.41 | 3.94M | 155,000 | D | ↗ |
| 2026-01-05 | Wilson Mark Andrew | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-11-10 | Long Daniel D. | Officer | S-Sale | D | Common Stock | 3,501 | 18.06 | 63.2K | 92,911 | D | ↗ |
| 2025-09-25 | Gottesdiener Keith Michael | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-18 | Klein Uwe | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,621 | 6.81 | 51.9K | 33,027 | D | ↗ |
| 2025-08-07 | Shaikhly Samira | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 11.70 | 351.0K | 30,000 | D | ↗ |
| 2025-08-07 | Long Daniel D. | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 11.70 | 351.0K | 30,000 | D | ↗ |
| 2025-08-07 | Labrucherie Gil M | Officer | A-Award | A | Stock Option (Right to Buy) | 37,500 | 11.70 | 438.8K | 37,500 | D | ↗ |
| 2025-08-07 | Klein Uwe | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 11.70 | 351.0K | 30,000 | D | ↗ |
| 2025-08-07 | Kim Jae B. | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 11.70 | 643.5K | 55,000 | D | ↗ |
| 2025-08-07 | Finer Jeffrey | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 11.70 | 2.46M | 210,000 | D | ↗ |
| 2025-08-07 | Bhatt Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 95,000 | 11.70 | 1.11M | 95,000 | D | ↗ |
| 2025-06-17 | Tong Jeffrey K | Director | A-Award | A | Stock Option (Right to Buy) | 16,623 | 10.24 | 170.2K | 16,623 | D | ↗ |
| 2025-06-17 | Simson Jake | Director | A-Award | A | Stock Option (Right to Buy) | 16,623 | 10.24 | 170.2K | 16,623 | D | ↗ |
| 2025-06-17 | Sharp Shalini | Director | A-Award | A | Stock Option (Right to Buy) | 16,623 | 10.24 | 170.2K | 16,623 | D | ↗ |
| 2025-06-17 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 16,623 | 10.24 | 170.2K | 16,623 | I | ↗ |
| 2025-06-17 | Ezekowitz Alan | Director | A-Award | A | Stock Option (Right to Buy) | 16,623 | 10.24 | 170.2K | 16,623 | D | ↗ |
| 2025-06-17 | Coulie Bernard | Director | A-Award | A | Stock Option (Right to Buy) | 16,623 | 10.24 | 170.2K | 16,623 | D | ↗ |
| 2025-06-17 | Bassan Abraham | Director | A-Award | A | Stock Option (Right to Buy) | 16,623 | 10.24 | 170.2K | 16,623 | D | ↗ |
| 2025-04-03 | Finer Jeffrey | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 2.76 | 13.8K | 826,907 | D | ↗ |
| 2025-04-02 | Finer Jeffrey | Director / Officer | M-Exempt | A | Common Stock | 50,000 | 2.76 | 138.0K | 821,907 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-621.5K
Shares Outstanding
45.08M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gil M. Labrucherie, CFA, J.D. Chief Financial Officer | 479.5K | 223.1K | — | 2.54M | — | 2.4K | 3.24M | 78.24% | ↗ |
| 2 | 2025 | Jeffrey Finer, M.D., Ph.D Chief Executive Officer | 635.0K | 401.6K | — | 1.89M | — | 5.0K | 2.93M | 64.49% | ↗ |
| 3 | 2025 | Liz Bhatt, M.S., M.B.A President and Chief Operating Officer | 500.0K | 230.0K | — | 855.8K | — | 5.0K | 1.59M | 53.80% | ↗ |
| 4 | 2024 | Jeffrey Finer, M.D., Ph.D. Chief Executive Officer | 550.2K | 365.9K | — | 3.80M | — | 3.0K | 4.72M | 80.53% | ↗ |
| 5 | 2024 | Jeffrey Finer, M.D., Ph.D Chief Executive Officer | 550.2K | 365.9K | — | 3.80M | — | 3.0K | 4.72M | 80.53% | ↗ |
| 6 | 2024 | Jae B. Kim, M.D. Chief Medical Officer | 125.1K | 108.1K | — | 1.63M | — | 3.0K | 1.87M | 87.37% | ↗ |
| 7 | 2024 | Liz Bhatt, M.S., M.B.A. Chief Operating Officer | 449.6K | 209.3K | — | 956.8K | — | 3.0K | 1.62M | 59.11% | ↗ |
| 8 | 2024 | Liz Bhatt, M.S., M.B.A President and Chief Operating Officer | 449.6K | 209.3K | — | 956.8K | — | 3.0K | 1.62M | 59.11% | ↗ |
| 9 | 2023 | Jeffrey Finer, M.D., Ph.D. Chief Executive Officer | 501.4K | 284.3K | — | 1.35M | — | 3.0K | 2.14M | 63.08% | ↗ |
| 10 | 2023 | Liz Bhatt, M.S., M.B.A. Chief Operating Officer | 413.3K | 203.3K | — | 264.2K | — | 3.0K | 883.7K | 29.89% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeffrey T. Finer | Co-Founder, Chief Executive Officer & Director | 1M | — |
| Elizabeth Bhatt | President & Chief Operating Officer | 735.0K | female |
| Gilbert Labrucherie | Chief Financial Officer | 711.7K | male |
| Samira Shaikhly | Chief People Officer | 536.5K | female |
| Jae Kim FACC | Chief Medical Officer | 486.3K | — |
| George Xu | Senior Director of Corporate Development & Portfolio Strategy | — | male |
| Mark A. Wilson | Chief Legal Officer | — | male |
| Patrick Sexton | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — |
| Richard Hansen | Vice President of Technology | — | male |
| Robert J. Lefkowitz | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — |
| Arthur Christopoulos BPHARM | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SEPN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
